3445-52-1

Usage

Chemical Properties

White powder

InChI:InChI=1/C5H6N2O2/c1-3-2-4(5(6)8)7-9-3/h2H,1H3,(H2,6,8)

Upstream product

• 39499-34-8 5-methyl-3-isoxazolyl chloride 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 3209-72-1 ethyl 5-methylisoxazole-3-carboxylate 
• 61672-67-1 5-methyl-isoxazole-3-carbonyl azide 

Downstream Products

• 57351-99-2 5-methyl-1,2-oxazole-3-carbonitrile 
• 77358-26-0 5-methyl-isoxazole-3-carbothioic acid amide 
• 139443-18-8 N-(2-methoxycarbonylphenylsulphonyl)-5-methyl-isoxazole-3-carboxamide 
• 154016-48-5 (5-methyl-3-isoxazolyl)methylamine 
• 196810-48-7 (S)-2-(2-Benzoyl-phenylamino)-3-(4-{2-[5-methyl-2-(5-methyl-isoxazol-3-yl)-thiazol-4-yl]-ethoxy}-phenyl)-propionic acid methyl ester 

Relevant academic research and scientific papers

Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity

The mineralocorticoid receptor (MR) is a nuclear hormone receptor involved in the regulation of body fluid and electrolyte homeostasis. In this study we explore selectivity triggers for a series of nonsteroidal MR antagonists to improve selectivity over other members of the oxosteroid receptor family. A biaryl sulfonamide compound was identified in a high-throughput screening (HTS) campaign. The compound bound to MR with pKi=6.6, but displayed poor selectivity over the glucocorticoid receptor (GR) and the progesterone receptor (PR). Following X-ray crystallography of MR in complex with the HTS hit, a compound library was designed that explored an induced-fit hypothesis that required movement of the Met852 side chain. An improvement in MR selectivity of 11- to 79-fold over PR and 23- to 234-fold over GR was obtained. Given the U-shaped binding conformation, macrocyclizations were explored, yielding a macrocycle that bound to MR with pKi=7.3. Two protein–ligand X-ray structures were determined, confirming the hypothesized binding mode for the designed compounds.

INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (I), (II) or (IV), or pharmaceutically acceptable salts and solvates thereof, which are useful as inhibitors of the Hepatitis C virus (HCV) protease enzyme and are also useful for the treatment of HCV infections in HCV--infected mammals, including humans. The present invention also provides pharmaceutical compositions comprising compounds of formula (I), (II) or (IV), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formulas (I), (II) and (IV).